jueves, 19 de noviembre de 2026

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets to treat neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. This is the first approved therapy capable of crossing the blood-brain barrier to address the neurological symptoms of GD3, a rare and progressive condition that has long lacked effective treatment options for its most debilitating manifestations. Approval was supported by data from a randomized, double-blind, multicenter clinical study in which patients treated with Infilbray demonstrated clinically meaningful neurological improvement compared to those continuing enzyme replacement therapy over 52 weeks. Healthcare providers are encouraged to review the full prescribing information for complete details on indication, dosing, and important safety information, including important safety considerations related to mood changes, potential cataracts in pediatric patients, potential risks to the fetus in pregnancy, and potential drug interactions, when considering treatment for eligible patients. Cases of suicidal ideation and behavior have been reported in patients receiving Infilbray. Healthcare providers should assess psychiatric risk before starting treatment and monitor patients throughout therapy. Patients and caregivers should seek prompt medical attention if new or worsening depression or thoughts of self-harm occur.

No hay comentarios:

Publicar un comentario